Navigation Links
Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer

of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the company's ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company's filings with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, Bristol-Myers Squibb built a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists at Bristol-Myers Squibb's Pharmaceutical Research Institute are studying ways to improve current cancer treatments and identify better, more effective medicines for the future.

Bristol-Myers Squibb is a global pharmaceutica
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
5. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
(Date:8/4/2015)... Medical Services Holdings Limited ("Concord Medical", or the "Company") (NYSE: ... of the largest network of radiotherapy and diagnostic imaging centers ... release its financial results for the second quarter of 2015 ... Management will hold a conference call to discuss the results ... 2015 (8:00 p.m. in Beijing / ...
(Date:8/4/2015)... 2015 BioElectronics Corporation (OTC Pink: BIEL), ... Therapy medical devices, announced today that its registry ... trial device has been published in the prominent ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain ... assessment.  Chronic pain is a ...
(Date:8/4/2015)... 04, 2015 Research ... addition of Jain PharmaBiotech,s new report "Animal ... their offering. This report describes and ... medicine and pharmaceuticals as well as improvement in ... in the application of biotechnology to manage genetic ...
Breaking Medicine Technology:Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 3
... Codexis, Inc. (NASDAQ: CDXS ) today announced financial ... Third Quarter Financial Highlights:Revenue: For the third ... an increase of 23% from $27.1 million in the third ... over the prior year quarter driven primarily by an increase ...
... 1, 2011 Every year thousands of children are hospitalized ... for them. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Teens share ... by colorful pills that look like candy. ... how you can prevent harm by locking your medicine up. ...
Cached Medicine Technology:Codexis Reports Third Quarter 2011 Results 2Codexis Reports Third Quarter 2011 Results 3Codexis Reports Third Quarter 2011 Results 4Codexis Reports Third Quarter 2011 Results 5Codexis Reports Third Quarter 2011 Results 6Codexis Reports Third Quarter 2011 Results 7Codexis Reports Third Quarter 2011 Results 8
(Date:8/4/2015)... ... August 04, 2015 , ... Wimbledon Health ... echocardiogram, and NCV testing, announced their collegiate division, Wimbledon U , continues ... abnormalities one program at a time. , “Wimbledon U welcomes the ...
(Date:8/4/2015)... ... August 04, 2015 , ... Angelina Jolie is in it ... of women every year. Dr. Angela DeRosa, DO, MBA, CPE aka “Dr. ... takes the scary unknown out of menopause. , Myth #1: Menopause only affects ...
(Date:8/4/2015)... ... August 04, 2015 , ... Seedstock’s 4th ... Nov. 3 – 4, 2015, at UC San Diego, will explore innovations that ... food access, and manage resources efficiently against the dueling backdrop of a lingering ...
(Date:8/4/2015)... ... August 04, 2015 , ... 24/7 Care At Home ... Riverside, and San Bernardino, today announced that the U.S. Department of Veteran’s Affairs (VA) ... Care At Home’s agency is well on the path to meeting the aspirational goals ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... label design, product packaging, and fulfillment services, joined over 200 other Long Island-based ... was held on Tuesday, July 28th at Jones Beach State Park in Wantagh, ...
Breaking Medicine News(10 mins):Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2
... and online education. , ... Seattle (PRWEB) November 4, ... their new website, online nursing degree programs and request ... students with schools, Online Nursing Career also aims to provide students ...
... are Precise and More Comfortable for Cancer Patients, ... at Cancer,Care Associates in Fresno, California have commenced ... from Varian,Medical Systems (NYSE: VAR ) that ... be completed two to eight times,faster than was ...
... First U.S. Product Will Be Sold by A Uniquely-Trained Sales ... ... ProStrakan Group plc,(LSE: PSK) today announced that SANCUSO(R) (Granisetron Transdermal System),is ... the United States. Sancuso was approved by,the U.S. Food and Drug Administration ...
... pose severe public health threat, especially in underdeveloped areas ... pose an important but neglected threat to global public ... in this week,s PLoS Medicine , estimates that ... occur annually, while suggesting the numbers could be as ...
... Extensive Information to Patients and Physicians -, ... ULU ),today announced that it has launched ... both health care professionals and patients on,the clinical ... information, demonstration of the use of,Altrazeal(TM) and product ...
... XOMA Ltd. (Nasdaq:,XOMA), a leader in the discovery ... Engle, Chairman and CEO of XOMA, is scheduled ... Investment Conference. The,presentation will take place in New ... An audio webcast of the presentation will ...
Cached Medicine News:Health News:Online Nursing Degree Seekers Gain a New Education Resource: OnlineNursingCareer.com 2Health News:Central California Doctors Now Using Fast RapidArc(TM) Radiotherapy Technology to Battle Cancer 2Health News:Central California Doctors Now Using Fast RapidArc(TM) Radiotherapy Technology to Battle Cancer 3Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 3Health News:ULURU Inc. Announces the Launch of the Altrazeal(TM) Website 2Health News:ULURU Inc. Announces the Launch of the Altrazeal(TM) Website 3Health News:XOMA to Present at the Rodman and Renshaw Annual Global Investment Conference on November 11 2Health News:XOMA to Present at the Rodman and Renshaw Annual Global Investment Conference on November 11 3
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Medicine Products: